Journal of Cancer Research and Clinical Oncology

, Volume 137, Issue 3, pp 521–532

Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol

  • Qiang-ling Sun
  • Hui-fang Sha
  • Xiao-hua Yang
  • Guo-liang Bao
  • Jing Lu
  • Yin-yin Xie
Original Paper
  • 654 Downloads

Abstract

Purpose

Paclitaxel is used as the first-line chemotherapy for Non-Small Cell Lung Cancer (NSCLC), but acquired resistance becomes a critical problem. Several mechanisms have been proposed in paclitaxel resistance, but they are not sufficient to exhaustively explain this resistance emergence. To better investigate molecular resistance mechanisms, a comparative proteomic approach was carried out to identify differentially expressed proteins between human lung adenocarcinoma A549 cell line (paclitaxel sensitive) and A549-Taxol cell line (acquired resistant).

Methods

A paclitaxel-resistant subline (A549-Taxol) derived from the parental-sensitive cell line A549 was established by stepwise selection by paclitaxel. Total proteins in the two cell lines were separated by fluorescent differential gel electrophoresis (DIGE). Image analysis was carried out with the DeCyder 2D 6.5 software. Proteins associated with chemoresistance process were identified by matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry (MALDI-TOF–MS/MS). Some key molecules were valuated by Western blot.

Results

Thirty proteins were identified and grouped into eight main functional classes according to the biological processes in which they are likely to participate, i.e. signal transduction, cytoskeleton, redox reaction, energy and metabolism, and so on. Alterations of these processes might be involved in paclitaxel resistance. Most of the proteins showed mitochondrial and cytoplasm location. The up-regulation of CK8, CK18, ALDH1, CAST and ANX I in A549-Taxol cell line was verified by Western blot, in coincidence with the data obtained from proteomic analysis.

Conclusion

For the first time, differentially expressed proteins between paclitaxel-sensitive cell line and paclitaxel-resistant one were explored by comparative proteomic approach in human lung adenocarcinoma. It may be useful for further studying of resistance mechanisms and screening of resistance biomarkers, so as to develop tailored therapeutic strategies.

Keywords

Chemoresistance Non-Small Cell Lung Cancer (NSCLC) Paclitaxel Two-dimensional difference gel electrophoresis (2D-DIGE) 

Abbreviations

2-DE

Two-dimensional gel electrophoresis

CK8

Cytokeratin-8

CK18

Cytokeratin-18

G6PD

Glucose-6-phosphate 1-dehydrogenase

RALDH1

Retinal dehydrogenase 1

References

  1. Bergman PJ (2003) Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract 33:651–667CrossRefPubMedGoogle Scholar
  2. Board P, Harris M, Flanagan J, Langton L, Coggan M (1998) Genetic heterogeneity of the structure and function of GSTT2 and GSTP1. Chem Biol Interact 111–112:83–89CrossRefPubMedGoogle Scholar
  3. Canuto RA, Ferro M, Muzio G, Bassi AM, Leonarduzzi G, Maggiora M, Adamo D, Poli G, Lindahl R (1994) Role of aldehyde metabolizing enzymes in mediating effects of aldehyde products of lipid peroxidation in liver cells. Carcinogenesis 15:1359–1364CrossRefPubMedGoogle Scholar
  4. Caulin C, Ware CF, Magin TM, Oshima RG (2000) Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 149:17–22CrossRefPubMedGoogle Scholar
  5. Emori Y, Imajoh-Ohmi S, Maki M (1992) Calpain and calpastatin–structure and function. Seikagaku 64:1201–1224PubMedGoogle Scholar
  6. Fais S, De Milito A, Lozupone F (2005) The role of FAS to ezrin association in FAS-mediated apoptosis. Apoptosis 10:941–947CrossRefPubMedGoogle Scholar
  7. Gautreau A, Poullet P, Louvard D, Arpin M (1999) Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:7300–7305CrossRefPubMedGoogle Scholar
  8. Gervasoni JE Jr, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S (2004) An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res 24:2617–2626PubMedGoogle Scholar
  9. Gilbert S, Loranger A, Daigle N, Marceau N (2001) Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 154:763–773CrossRefPubMedGoogle Scholar
  10. Gomperts BN, Gong-Cooper X, Hackett BP (2004) Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells. J Cell Sci 117:1329–1337CrossRefPubMedGoogle Scholar
  11. Gonzalez-Santiago L, Alfonso P, Suarez Y, Nunez A, Garcia-Fernandez LF, Alvarez E, Munoz A, Casal JI (2007) Proteomic analysis of the resistance to aplidin in human cancer cells. J Proteome Res 6:1286–1294CrossRefPubMedGoogle Scholar
  12. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB (1995) Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270:31269–31275CrossRefPubMedGoogle Scholar
  13. Impens F, Van Damme P, Demol H, Van Damme J, Vandekerckhove J, Gevaert K (2008) Mechanistic insight into taxol-induced cell death. Oncogene 27:4580–4591CrossRefPubMedGoogle Scholar
  14. Inada H, Izawa I, Nishizawa M, Fujita E, Kiyono T, Takahashi T, Momoi T, Inagaki M (2001) Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol 155:415–426CrossRefPubMedGoogle Scholar
  15. Ishii T, Teramoto S, Matsuse T (2004) GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. Cancer Lett 216:89–102CrossRefPubMedGoogle Scholar
  16. Jaffrezou JP, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, Sikic BI (1995) Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 7:517–527PubMedGoogle Scholar
  17. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30CrossRefPubMedGoogle Scholar
  18. Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, Gauduchon P, Baudin B (2006) Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1–R10. Proteomics 6:5183–5192CrossRefPubMedGoogle Scholar
  19. Li L, Luan Y, Wang G, Tang B, Li D, Zhang W et al (2004) Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med 14:257–264PubMedGoogle Scholar
  20. Lilley KS (2003) Protein profiling using two-dimensional difference gel electrophoresis (2-D DIGE). Curr Protoc Protein Sci Chapter 22: Unit 22 22Google Scholar
  21. Liu Y, Liu H, Han B, Zhang JT (2006) Identification of 14–3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66:3248–3255CrossRefPubMedGoogle Scholar
  22. Luciani F, Molinari A, Lozupone F, Calcabrini A, Lugini L, Stringaro A, Puddu P, Arancia G, Cianfriglia M, Fais S (2002) P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood 99:641–648CrossRefPubMedGoogle Scholar
  23. Murachi T (1990) Calpain and calpastatin. Rinsho Byori 38:337–346PubMedGoogle Scholar
  24. Murphy L, Henry M, Meleady P, Clynes M, Keenan J (2008) Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim Biophys Acta 1784:1184–1191PubMedGoogle Scholar
  25. Parekh H, Simpkins H (1997) The transport and binding of taxol. Gen Pharmacol 29:167–172PubMedGoogle Scholar
  26. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014CrossRefPubMedGoogle Scholar
  27. Sakai T (2006) Drug resistance and cell survival mechanisms for anticancer drugs. Nippon Yakurigaku Zasshi 127:342–347CrossRefPubMedGoogle Scholar
  28. Sangrajrang S, Fellous A (2000) Taxol resistance. Chemotherapy 46:327–334CrossRefPubMedGoogle Scholar
  29. Seve P, Dumontet C (2005) Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 5:73–88CrossRefPubMedGoogle Scholar
  30. Timms JF, Cramer R (2008) Difference gel electrophoresis. Proteomics 8:4886–4897CrossRefPubMedGoogle Scholar
  31. Tsukita S, Yonemura S (1997) ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 9:70–75CrossRefPubMedGoogle Scholar
  32. Wang YF, Chen CY, Chung SF, Chiou YH, Lo HR (2004) Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells. Cancer Chemother Pharmacol 54:322–330CrossRefPubMedGoogle Scholar
  33. Wendt A, Thompson VF, Goll DE (2004) Interaction of calpastatin with calpain: a review. Biol Chem 385:465–472CrossRefPubMedGoogle Scholar
  34. Wilson TR, Longley DB, Johnston PG (2006) Chemoresistance in solid tumours. Ann Oncol 17(Suppl 10):x315–x324CrossRefPubMedGoogle Scholar
  35. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19CrossRefPubMedGoogle Scholar
  36. Zhang JT, Liu Y (2007) Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 33:741–756CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Qiang-ling Sun
    • 1
  • Hui-fang Sha
    • 1
  • Xiao-hua Yang
    • 1
  • Guo-liang Bao
    • 1
  • Jing Lu
    • 2
  • Yin-yin Xie
    • 2
  1. 1.Basic Research LaboratoryShanghai Chest Hospital Affiliated to Shanghai Jiaotong UniversityShanghaiChina
  2. 2.Institute of HematologyRuijin Hospital of Shanghai Jiaotong UniversityShanghaiChina

Personalised recommendations